Does Nattokinase Cause Joint Pain?

Nattokinase is one of the most-studied fibrinolytic enzymes on the supplement market — yet the question "does nattokinase cause joint pain?" shows up in search boxes far more often than the clinical literature would predict.

In the 3-year Nattokinase Atherothrombotic Prevention Study (NAPS) of 265 adults, joint-related adverse events were rare and roughly balanced between the nattokinase and placebo groups. No serious joint events were attributed to the enzyme. The full picture has a few nuances worth understanding — especially if you're on a blood thinner.

Table of Contents

1. The Short Answer: What Clinical Evidence Actually Shows
2. What the Largest Trials Found About Joint-Related Events
3. Why People May Wrongly Attribute Joint Pain to Nattokinase
4. The Real Concern: Hemarthrosis Risk With Anticoagulants
5. Can Nattokinase Actually Help Joint Pain?
6. When to Stop Nattokinase: Red Flags to Watch For
7. BioAbsorb Nattokinase Enzyme: A Third-Party Tested Formulation
8. Frequently Asked Questions
9. Conclusion
10. Research References

The Short Answer: What Clinical Evidence Actually Shows

The direct answer to "does nattokinase cause joint pain?" is that current clinical evidence does not identify joint pain as a common or serious side effect of nattokinase at typical supplement doses. That answer is worth unpacking, because a lot of supplement-safety information online is either overconfident or evasive.

Nattokinase is a serine protease enzyme derived from natto, a fermented soybean food. It has been studied primarily for cardiovascular endpoints — blood pressure, plaque progression, fibrinolytic activity — and the adverse-event registries from these trials are the best available window into what nattokinase actually does to the body over weeks to years. Across those registries, the pattern is consistent: mild gastrointestinal effects are the most frequent complaints; bleeding-related events are the most serious concern; joint pain is not a recurring signal. For a broader safety context, see our complete guide to nattokinase benefits, dosage, and safety.

What the evidence does not support is the certainty that nattokinase never causes joint discomfort in any individual. Clinical trials sample a specific population, run for a defined period, and detect adverse events at a certain frequency. Rare or idiosyncratic reactions can happen with any supplement. The honest reading is: no meaningful signal in the trial data, and no plausible biological mechanism by which nattokinase would directly damage joint tissue.

What the Largest Trials Found About Joint-Related Events

The NAPS trial is the longest and most detailed nattokinase safety dataset available. Conducted by Howard Hodis and colleagues at the University of Southern California, NAPS randomized 265 participants with a median age of 65.3 years to nattokinase 2,000 FU daily or matching placebo for three years, tracking cardiovascular endpoints and adverse events across the entire cohort. Results were published in Clinical Hemorheology and Microcirculation in 2021.

The detailed adverse event breakdown reported on ClinicalTrials.gov itemizes musculoskeletal events in both groups. Osteoarthritis was recorded in 3 of 132 nattokinase participants (2.27%) versus 0 of 133 placebo participants — a small numerical difference against a background of many balanced or placebo-favoring categories. Muscle spasms occurred in 1 nattokinase participant and 1 placebo participant. Joint swelling was reported in 0 nattokinase versus 1 placebo participant. Arthritis was reported in 0 nattokinase versus 1 placebo participant. None of these differences reached statistical significance in a trial of this size, and no joint-related event was serious.

Beyond NAPS, a 2023 systematic review and meta-analysis in Reviews in Cardiovascular Medicine pooled 6 randomized trials with a combined 546 participants and reported no serious adverse events tied to musculoskeletal symptoms across the included studies. A separate 2024 double-blind trial in 178 stable coronary artery disease patients tested nattokinase alone and in combination with red yeast rice for 90 days — no adverse effects due to the interventions were reported. And a real-world safety study published in Nutrients in 2021 that followed vascular disease patients on nattokinase reported no adverse events, with confirmed systolic blood pressure reduction during supplementation.

The Memorial Sloan Kettering Cancer Center integrative medicine monograph — a widely-referenced authoritative source — lists the adverse events reported for nattokinase: allergic reactions in individuals sensitive to natto, one case of fatal internal bleeding in an elderly woman, and a valve thrombosis case in a patient who self-substituted nattokinase for warfarin. Joint pain is not on that list.

Why People May Wrongly Attribute Joint Pain to Nattokinase

If the trial data doesn't support nattokinase causing joint pain, why does the question keep surfacing? The answer is a familiar pattern in supplement-attributed side effects: correlation gets mistaken for causation.

Most nattokinase users are middle-aged or older adults taking the enzyme for cardiovascular support. The NAPS cohort had a median age of 65.3 years — an age band where joint discomfort and diagnosed arthritis are common baseline experiences in the general population. Joint symptoms in this demographic are the baseline, not the exception. When someone starts a new supplement and notices joint stiffness within days or weeks, the sequence feels causal even when the joint symptoms would have appeared anyway.

Three other factors muddy the picture. First, nattokinase is often stacked with other supplements — magnesium, vitamin K2, curcumin, fish oil — any of which can theoretically influence how a person feels. Second, some users start nattokinase around the same time they change their exercise routine or come off a prescription medication like a statin, which itself has well-documented muscle and joint effects. Third, brief mild gastrointestinal discomfort — which is a real, documented nattokinase side effect at higher doses — can be misread as generalized aches.

None of this means an individual's experience is wrong. It means the trial-level evidence does not support a mechanism by which nattokinase would cause new joint pain. If joint symptoms appear after starting nattokinase, the reasonable step is to pause the supplement briefly, note whether the symptoms improve, and consult a healthcare provider before restarting. That's the same clinical logic used to disentangle any new symptom from a new medication.

The Real Concern: Hemarthrosis Risk With Anticoagulants

There is one indirect way nattokinase could cause joint pain, and it deserves clear attention. Nattokinase has fibrinolytic and mild antiplatelet activity — meaning it acts on the same clotting-and-bleeding pathways as prescription blood thinners. When nattokinase is combined with anticoagulants like warfarin, direct oral anticoagulants (DOACs), or antiplatelet drugs like aspirin and clopidogrel, the effect on bleeding risk can be additive.

Bleeding into a joint — called hemarthrosis — is one of the specific complications of over-anticoagulation. A classic case series published in Arthritis & Rheumatism described three warfarin patients with knee hemarthrosis whose prothrombin times were all more than 2.4 times the control value at the time of joint bleeding. Symptoms persisted until warfarin was substantially decreased or discontinued. Warfarin-associated hemarthrosis, though relatively uncommon overall, is a well-recognised complication of excessive anticoagulation in the clinical literature.

Hemarthrosis typically presents as sudden, unexplained joint pain and swelling — often in a knee, sometimes without any trauma. This is not the vague background stiffness most people think of when they hear "joint pain." It's an acute event that warrants immediate medical evaluation.

Does adding nattokinase to warfarin actually push someone into this risk zone? The literature does not answer that question directly. Drugs.com's natural products review cites an unpublished study in which 12 patients on heparin plus aspirin or clopidogrel also received nattokinase 6,000 FU/day for 7 days — coadministration increased bleeding time and decreased D-dimer levels, with three unspecified temporary adverse reactions reported. The prudent interpretation: anyone on prescription anticoagulants or antiplatelets should not add nattokinase without physician supervision. For a fuller discussion of these interactions, see our article on nattokinase as a natural blood thinner.

Can Nattokinase Actually Help Joint Pain?

A more interesting question — and one better supported by mechanism research — is whether nattokinase might reduce joint discomfort rather than cause it. Systemic proteolytic enzymes as a class have a long history of use in inflammation management, and nattokinase has attracted specific attention here.

A 2024 narrative review in Expert Review of Cardiovascular Therapy concluded that nattokinase demonstrates fibrinolytic, antithrombotic, anti-inflammatory, and antioxidant effects — and can be considered an adjuvant strategy for non-communicable diseases where inflammation and oxidative stress are central. The review synthesizes preclinical work showing nattokinase modulates inflammatory signaling pathways, including reductions in pro-inflammatory cytokine release in cellular and animal models.

Two important caveats. First, most of the anti-inflammatory data comes from in vitro and animal studies. Human clinical trials specifically evaluating nattokinase for joint conditions like osteoarthritis or rheumatoid arthritis are not yet published in the peer-reviewed literature. Second, nattokinase's proposed mechanism for joint benefit is indirect — improving circulation to inflamed tissues and reducing fibrin-related inflammation — rather than acting on the joint capsule directly.

The takeaway is measured: the biological plausibility for nattokinase to help joint discomfort is stronger than the plausibility for it to cause discomfort, but neither claim rises to the level of established clinical evidence. If joint health is a primary reason someone is considering nattokinase, they should approach it as a general anti-inflammatory support rather than a targeted joint treatment.

When to Stop Nattokinase: Red Flags to Watch For

Joint pain is not among the primary red flags for stopping nattokinase, but a small set of symptoms genuinely warrant discontinuation and medical evaluation. Recognizing them matters more than tracking vague aches.

The first is allergic reaction. Because nattokinase is derived from fermented soybeans, it can trigger allergy in people sensitive to natto specifically. A case series in Allergology International described seven patients who experienced late-onset anaphylaxis from natto, with symptoms including generalized urticaria, dyspnea, and in several cases loss of consciousness. Anaphylaxis specifically to purified nattokinase has also been reported in patients with pre-existing fermented soybean allergy. Sudden urticaria, dyspnea, or facial swelling after taking nattokinase requires immediate medical attention.

The second is unusual bleeding or bruising — including sudden, unexplained joint swelling of the kind associated with hemarthrosis. Prolonged nosebleeds, gum bleeding, blood in stool or urine, or unusual bruising all warrant stopping nattokinase and contacting a physician, especially for anyone on an anticoagulant or antiplatelet drug.

The third is sustained gastrointestinal discomfort. Mild, brief nausea or bloating in the first days is expected in a small percentage of users and typically resolves without intervention. Symptoms that persist beyond a week, or that escalate, are a signal to reassess dose, timing, or continued use.

None of these red flags map to gradual joint pain. If joint symptoms are the primary concern, the most useful diagnostic step is to briefly discontinue nattokinase, monitor for a week to ten days, and observe whether the symptoms change independently of the supplement.

BioAbsorb Nattokinase Enzyme: A Third-Party Tested Formulation

For readers evaluating a specific product, BioAbsorb Nutraceuticals' Nattokinase Enzyme is formulated at 100 mg per capsule standardized to 2,000 fibrinolytic units (FU) — the same activity level used in the NAPS trial and the majority of published clinical research. This matters because FU is a functional activity measurement, and identical milligram doses of different nattokinase preparations can vary substantially in real enzyme activity.

Three formulation choices are worth understanding in the context of side effect risk. First, the capsules use DRcaps delayed-release veggie capsule technology — designed to protect the enzyme from stomach acid and deliver it intact to the small intestine, without the phthalates and plasticizers found in some enteric-coated capsules. Second, the formulation is free of vitamin K2, which is a deliberate design choice — it allows longer-term or higher-dose use without stacking K2 concerns. Third, the product is manufactured in a Canadian GMP-certified facility with each batch third-party tested for nattokinase activity, heavy metals, gluten, and microbial contaminants — the kind of transparency that matters when the primary safety questions relate to enzyme quality and contamination rather than the enzyme itself.

The dosing protocol is a single capsule once daily on an empty stomach. The 180-capsule bottle is priced at $49.87 — roughly $0.28 per day for a formulation matching the clinical dose. For readers new to nattokinase, our nattokinase dosage guide walks through how the 2,000 FU dose was established.

Frequently Asked Questions

Can nattokinase cause muscle or joint aches when you first start taking it?

Clinical trials have not identified muscle or joint aches as a common early adverse event. The most frequently reported first-week complaints are mild gastrointestinal discomfort — nausea, mild stomach upset — which typically resolves without intervention. Persistent aches after starting nattokinase warrant a temporary pause and a conversation with a healthcare provider to rule out unrelated causes.

Is nattokinase safe for people with arthritis?

Nattokinase has not been specifically studied for arthritis management in published human trials, but the safety data from cardiovascular trials — including a 3-year study in adults with a median age above 65 — does not show excess joint-related adverse events. People with arthritis should discuss nattokinase with their physician before starting, particularly if they take NSAIDs, aspirin, or prescription anticoagulants, all of which can additively affect bleeding risk.

Could nattokinase cause hemarthrosis (bleeding into a joint)?

Nattokinase alone at standard doses has not been linked to hemarthrosis in clinical trials. The theoretical concern arises when nattokinase is combined with prescription anticoagulants like warfarin — where hemarthrosis is a documented complication of excessive anticoagulation. Sudden, unexplained joint pain and swelling in someone on blood-thinning medication requires immediate medical evaluation.

Should I stop nattokinase if I develop joint pain?

A brief pause of seven to ten days is a reasonable diagnostic step to see whether joint symptoms change independently of the supplement. If pain resolves during the pause and returns after restarting, discuss this pattern with a healthcare provider before continuing. If pain is severe, sudden, or accompanied by swelling and bruising, stop nattokinase and seek medical evaluation promptly.

Does nattokinase have anti-inflammatory effects that could help joints?

Preclinical research suggests nattokinase has anti-inflammatory and antioxidant activity, and improving circulation may indirectly benefit inflamed tissues. However, no published human trials have specifically evaluated nattokinase for arthritis or joint pain. The evidence is currently mechanism-level rather than outcome-level, so nattokinase should not be positioned as a targeted joint treatment.

Is joint pain listed as a known nattokinase side effect?

Joint pain is not listed as a common or serious nattokinase side effect by major reference sources including the Memorial Sloan Kettering Cancer Center integrative medicine monograph and published clinical trial adverse-event registries. The documented side effect profile focuses on mild gastrointestinal symptoms, allergic reactions in soy-sensitive individuals, and bleeding-related events primarily in combination with anticoagulants.

Conclusion

The clinical evidence does not support nattokinase as a cause of joint pain at standard supplement doses — but the more important safety story is the bleeding-related interaction with anticoagulants, where hemarthrosis is a documented concern. For a clinically-dosed 2,000 FU formulation with third-party testing and DRcaps delivery, consider BioAbsorb Nattokinase Enzyme, and always speak with your healthcare provider before starting if you take blood-thinning medications.

Research References

1. Hodis HN, Mack WJ, Meiselman HJ, et al. Nattokinase atherothrombotic prevention study: A randomized controlled trial. Clinical Hemorheology and Microcirculation. 2021;78(4):339-353. doi:10.3233/CH-211147. PubMed
2. Nattokinase Atherothrombotic Prevention Study — detailed adverse event registry. ClinicalTrials.gov Identifier: NCT02080520. ClinicalTrials.gov
3. Li X, Long J, Gao Q, et al. Nattokinase Supplementation and Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Reviews in Cardiovascular Medicine. 2023;24(8):234. doi:10.31083/j.rcm2408234. PMC
4. Gallelli G, Di Mizio G, Palleria C, et al. Data Recorded in Real Life Support the Safety of Nattokinase in Patients with Vascular Diseases. Nutrients. 2021;13(6):2031. PMC
5. Granito M, Alvarenga L, Ribeiro M, et al. Nattokinase as an adjuvant therapeutic strategy for non-communicable diseases: a review of fibrinolytic, antithrombotic, anti-inflammatory, and antioxidant effects. Expert Review of Cardiovascular Therapy. 2024;22(10):565-574. doi:10.1080/14779072.2024.2416663. Taylor & Francis Online
6. Liu M, Xu Z, Wang Z, et al. Lipid-lowering, antihypertensive, and antithrombotic effects of nattokinase combined with red yeast rice in patients with stable coronary artery disease: a randomized, double-blinded, placebo-controlled trial. Frontiers in Nutrition. 2024;11:1380727. doi:10.3389/fnut.2024.1380727. Frontiers
7. Wild JH, Zvaifler NJ. Hemarthrosis associated with sodium warfarin therapy. Arthritis & Rheumatism. 1976;19(1):98-102. doi:10.1002/art.1780190117. PubMed
8. Inomata N, Osuna H, Kawano K, Yamaguchi J, Yanagimachi M, Matsukura S, Ikezawa Z. Late-onset anaphylaxis after ingestion of Bacillus Subtilis-fermented soybeans (Natto): clinical review of 7 patients. Allergology International. 2007;56(3):257-261. doi:10.2332/allergolint.O-06-460. PubMed
9. Memorial Sloan Kettering Cancer Center. Nattokinase — Integrative Medicine Herb Monograph. MSKCC
10. Nattokinase — Uses, Benefits & Dosage. Drugs.com Natural Products Database. Drugs.com
11. BioAbsorb Nutraceuticals. Official Website. bioabsorbnutraceuticals.com
12. BioAbsorb Nutraceuticals. Nattokinase Enzyme — 100 mg / 2,000 FU / DRcaps / 180 Veggie Capsules. Product Page. BioAbsorb

About the Author

David Kimbell is a health writer, digital entrepreneur and former aerospace engineer, based in Ottawa, Canada. He loves translating complex science into clear, actionable guidance for consumers seeking evidence-based solutions.

---

Important Disclaimers

Medical Disclaimer: This article provides educational information only and is not intended as medical advice. Always consult with a qualified healthcare provider before starting any new supplement, especially if you have existing health conditions, take medications, or are pregnant or nursing.

FDA/Health Canada Statement: These statements have not been evaluated by the Food and Drug Administration or Health Canada. This product is not intended to diagnose, treat, cure, or prevent any disease.